What is HC Wainwright’s Forecast for PSTV FY2029 Earnings?

Plus Therapeutics, Inc. (NASDAQ:PSTV) – Research analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of Plus Therapeutics in a note issued to investors on Friday, March 28th. HC Wainwright analyst S. Lee forecasts that the company will post earnings per share of $0.95 for the year. HC Wainwright currently has a “Buy” rating and a $5.50 target price on the stock. The consensus estimate for Plus Therapeutics’ current full-year earnings is ($2.30) per share.

Plus Therapeutics (NASDAQ:PSTV) last announced its earnings results on Thursday, March 27th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The company had revenue of $1.80 million for the quarter, compared to analyst estimates of $1.19 million.

Other research analysts have also recently issued research reports about the company. D. Boral Capital reissued a “buy” rating and issued a $9.00 target price on shares of Plus Therapeutics in a research note on Friday. Ascendiant Capital Markets reduced their price objective on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, December 9th.

Plus Therapeutics Price Performance

Shares of NASDAQ:PSTV opened at $0.95 on Monday. The company’s fifty day moving average price is $1.10 and its 200-day moving average price is $1.23. The firm has a market capitalization of $5.60 million, a price-to-earnings ratio of -0.38 and a beta of 0.73. Plus Therapeutics has a one year low of $0.24 and a one year high of $2.67.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.